AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”

AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”

AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”



TOKYO, Sep 13, 2021 – (JCN Newswire) – AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. revealed today that, on September 13, 2021, the business introduced “Humira Support Tool Ordering Service for Patients” an effort meant to enhance clients’ adherence to Humira treatment.

“Humira Support Tool Ordering Service for Patients” is a free-of-charge service that helps clients on Humira treatment by straight providing assistance tools to their house or other asked for area. Clients can utilize this service by using on the site or utilizing a designated type to demand assistance tools such as containers for disposal of utilized syringes, bags for disposal of utilized pens, disease-specific health management note pads, and disease-specific medication guides for clients. The asked for assistance tools are provided to their house or other preferred area free-of-charge.

Formerly, clients got the assistance tools they required throughout a center see. When the assistance tools they required were not readily available at the center, it took some time to provide the assistance tools to clients, possibly leading to unavailability of the tools when required. In addition, some large-sized tools, such as containers for disposal of utilized syringes, put a concern on clients who needed to bring them house. This service is meant to permit clients to reduce the time needed to get assistance tools and lower the problem of bring them.

In Japan, AbbVie is the marketing and production permission holder for Humira. Abbvie and Eisai are co-promoting Humira for the indicators in the fields of rheumatoid arthritis, plaque psoriasis, arthropathic psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, uveitis, pustular psoriasis, hidradenitis suppurativa and pyoderma gangrenosum. For the indicators in the field of intestinal illness (i.e., Crohn’s illness, digestive tract Bechet’s illness and ulcerative colitis), AbbVie is co-promoting Humira with EA Pharma, commissioned by Eisai for promo.

Through offering “Humira Support Tool Ordering Service for Patients,” AbbVie, Eisai, and EA Pharma are devoted to more boosting client assistance programs and adding to better treatment adherence.

About HUMIRA

HUMIRA is a completely human anti-TNF-alpha monoclonal antibody. In Japan, it is authorized for “the treatment of rheumatoid arthritis (consisting of inhibition of the development of structural damage); hidradenitis suppurativa, pyoderma gangrenosum, the treatment of plaque psoriasis, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis *, digestive tract Behcet’s illness, and non-infectious intermediate, posterior and panuveitis that are refractory to the traditional treatments, induction and upkeep treatment for moderate to seriously active Crohn’s illness (restricted to clients who have had an insufficient action to traditional treatment), and treatment of moderate to serious ulcerative colitis (restricted to clients who have had an insufficient reaction to standard treatment).”

HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL is authorized. HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL are yet to be authorized.

Nonproprietary name: Adalimumab

Brand name: Fully Human Anti- TNF-alpha Monoclonal Antibody “HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL; HUMIRA for Subcutaneous Injection 40 mg Syringe 0.4 mL; HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL; HUMIRA for Subcutaneous Injection 40 mg Pen 0.4 mL; and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL”

About AbbVie

AbbVie’s objective is to find and provide ingenious medications that fix severe health problems today and attend to the medical difficulties of tomorrow. We aim to have an exceptional influence on individuals’s lives throughout a number of essential healing locations: immunology, oncology, neuroscience, eye care, virology, females’s health and gastroenterology, in addition to services and products throughout its Allergan Aesthetics portfolio. For more details about AbbVie, please visit us at www.abbvie.com.

About Eisai

Eisai Co., Ltd. is a leading international research study and development-based pharmaceutical business headquartered in Japan. We specify our business objective as “offering initially believed to clients and their households and to increasing the advantages healthcare offers,” which we call our human healthcare (hhc) viewpoint. With around 10,000 workers working throughout our worldwide network of R&D centers, producing websites and marketing subsidiaries, we make every effort to understand our hhc viewpoint by providing ingenious items to attend to unmet medical requirements, with a specific focus in our tactical locations of Neurology and Oncology. To learn more about Eisai Co., Ltd., please see www.eisai.com.

About EA Pharma

EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for intestinal illness location, was developed in April 2016 by combination of the intestinal organization system with more than 60 year’s history of the Eisai Group and the intestinal company system of the Ajinomoto Group having amino acid as its company core. EA Pharma Co., Ltd., is an intestinal specialized pharmaceutical business with an amount chain covering R&D, production & logistics and sales & marketing.

For more details on EA Pharma Co., Ltd., please see https://www.eapharma.co.jp/en

Copyright ©2021 JCN Newswire. All rights booked. A department of Japan Corporate News Network.

Read More

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *